OA12416A - Composition pharmaceutique de dronedarone pour administration parentérale. - Google Patents

Composition pharmaceutique de dronedarone pour administration parentérale. Download PDF

Info

Publication number
OA12416A
OA12416A OA1200300152A OA1200300152A OA12416A OA 12416 A OA12416 A OA 12416A OA 1200300152 A OA1200300152 A OA 1200300152A OA 1200300152 A OA1200300152 A OA 1200300152A OA 12416 A OA12416 A OA 12416A
Authority
OA
OAPI
Prior art keywords
pharmaceutical composition
composition according
cyclodextrin
dronedarone
alkali metal
Prior art date
Application number
OA1200300152A
Other languages
English (en)
French (fr)
Inventor
Frederique Bourriague-Seve
Thierry Breul
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of OA12416A publication Critical patent/OA12416A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
OA1200300152A 2000-12-11 2001-12-10 Composition pharmaceutique de dronedarone pour administration parentérale. OA12416A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (1)

Publication Number Publication Date
OA12416A true OA12416A (fr) 2006-04-18

Family

ID=8857483

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300152A OA12416A (fr) 2000-12-11 2001-12-10 Composition pharmaceutique de dronedarone pour administration parentérale.

Country Status (31)

Country Link
US (1) US6939865B2 (hu)
EP (1) EP1343473B1 (hu)
JP (1) JP4399161B2 (hu)
KR (1) KR100849758B1 (hu)
CN (1) CN1235566C (hu)
AR (1) AR031649A1 (hu)
AT (1) ATE348599T1 (hu)
AU (2) AU2002217229B2 (hu)
BG (1) BG66187B1 (hu)
BR (1) BR0116060B1 (hu)
CA (1) CA2427375C (hu)
CZ (1) CZ297788B6 (hu)
DE (1) DE60125411T2 (hu)
EA (1) EA005314B1 (hu)
FR (1) FR2817750B1 (hu)
HK (1) HK1055906A1 (hu)
HU (1) HU229372B1 (hu)
IL (2) IL155428A0 (hu)
IS (1) IS2349B (hu)
MA (1) MA26969A1 (hu)
ME (2) MEP20408A (hu)
MX (1) MXPA03005221A (hu)
NO (1) NO332294B1 (hu)
NZ (1) NZ525661A (hu)
OA (1) OA12416A (hu)
PL (1) PL199846B1 (hu)
RS (1) RS50348B (hu)
SK (1) SK287115B6 (hu)
TW (1) TWI246926B (hu)
WO (1) WO2002047660A1 (hu)
ZA (1) ZA200303406B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
AR072950A1 (es) 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
SG11201500123XA (en) * 2012-07-12 2015-02-27 Sanofi Sa Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
WO2022083636A1 (zh) * 2020-10-20 2022-04-28 上海博志研新药物技术有限公司 盐酸决奈达隆药物组合物、其制备方法及应用
TW202320751A (zh) * 2021-08-16 2023-06-01 大陸商上海博志研新藥物技術有限公司 鹽酸決奈達隆注射組合物、其製備方法及應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
ATE348599T1 (de) 2007-01-15
NO20031958D0 (no) 2003-04-29
HU229372B1 (en) 2013-11-28
HUP0500842A2 (hu) 2005-12-28
AU1722902A (en) 2002-06-24
BG107748A (bg) 2004-03-31
KR20030060985A (ko) 2003-07-16
AU2002217229B2 (en) 2006-05-18
IS2349B (is) 2008-04-15
FR2817750A1 (fr) 2002-06-14
CA2427375A1 (fr) 2002-06-20
CZ297788B6 (cs) 2007-03-28
PL362788A1 (en) 2004-11-02
WO2002047660A1 (fr) 2002-06-20
ME00083B (me) 2010-10-10
BR0116060B1 (pt) 2013-12-31
DE60125411D1 (de) 2007-02-01
SK7262003A3 (en) 2004-02-03
SK287115B6 (sk) 2009-12-07
CA2427375C (fr) 2011-02-01
IS6801A (is) 2003-04-30
NZ525661A (en) 2004-11-26
BR0116060A (pt) 2004-03-02
EA005314B1 (ru) 2004-12-30
EA200300406A1 (ru) 2003-10-30
ZA200303406B (en) 2004-05-03
CN1479610A (zh) 2004-03-03
IL155428A0 (en) 2003-11-23
JP2004528277A (ja) 2004-09-16
RS50348B (sr) 2009-11-10
FR2817750B1 (fr) 2003-02-21
MEP20408A (en) 2010-06-10
PL199846B1 (pl) 2008-11-28
KR100849758B1 (ko) 2008-07-31
EP1343473B1 (fr) 2006-12-20
YU46503A (sh) 2006-08-17
US6939865B2 (en) 2005-09-06
MXPA03005221A (es) 2004-03-26
CN1235566C (zh) 2006-01-11
NO332294B1 (no) 2012-08-20
JP4399161B2 (ja) 2010-01-13
TWI246926B (en) 2006-01-11
MA26969A1 (fr) 2004-12-20
EP1343473A1 (fr) 2003-09-17
NO20031958L (no) 2003-06-11
DE60125411T2 (de) 2007-10-11
US20040044070A1 (en) 2004-03-04
BG66187B1 (bg) 2011-12-30
AR031649A1 (es) 2003-09-24
IL155428A (en) 2007-10-31
HK1055906A1 (en) 2004-01-30
CZ20031612A3 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
CA2427375C (fr) Composition pharmaceutique de dronedarone pour administration parenterale
CA2222304C (fr) Composition pharmaceutique d'amiodarone pour administration parenterale
BE1003647A5 (fr) Composition pharmaceutique de nicardipine pour administration parenterale.
EP1037652B1 (fr) Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
EP1896016B1 (fr) Procede de solubilisation du metronidazole
CH644015A5 (fr) Solution aqueuse injectable a base d'oxytetracycline.
EP0949923B1 (fr) Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
CA3090570A1 (fr) Composition multiusage de torasemide
AU2008340179B2 (en) Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists
FR2839888A1 (fr) Complexes d'inclusion de fenofibrate et de cyclodextrine et composition pharmaceutique les renfermant
WO2004014360A2 (fr) Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
WO2009000504A2 (fr) Formulation injectable pour therapie photodynamique
FR2803515A1 (fr) Solution aqueuse stable de deoxyfructosazine
BE523649A (hu)
FR2923719A1 (fr) Compositions pharmaceutiques a base de derives d'azetidine